gene therapy – Page 8

Purespring Therapeutics Secures £80M ($105M) Series B Funding to Advance IgAN Gene Therapy into Clinical Trials

8 months ago talkbio0Tagged AAVS1 gene, Clinical Trials, gene therapy, glomerular kidney disease, IGA Glomerulonephritis, Kidney Diseases, Nephrotic Syndrome, Podocytes, Purespring, Series B

Purespring Therapeutics, IgAN gene therapy, kidney disease, Series B funding, clinical trials, AAV gene therapy, podocytes, nephrotic syndrome, glomerular kidney disease.

GEMMABio Secures $100M Partnership to Advance Rare Disease Gene Therapies in Brazil

8 months ago talkbio0Tagged Brazil, GEMMABio, gene therapy, health ministry

GEMMABio, gene therapy, Brazil, rare diseases, $100M partnership, health ministry

Astellas Expands Gene Therapy Portfolio with $2.2 Billion Deal for AviadoBio’s Frontotemporal Dementia Treatment

8 months ago talkbio0Tagged Astellas Pharma Inc., AVB-101, AviadoBio Ltd., Frontotemporal dementia, gene therapy, Mutation, Neurodegenerative Disorders, Pick Disease of the Brain, Progranulins

Astellas Pharma Inc., AviadoBio Ltd., Gene Therapy, Frontotemporal Dementia, FTD-GRN, AVB-101, Progranulin Mutations, Neurodegenerative Diseases

Gene Therapy Pioneer Jim Wilson Launches Franklin Biolabs, Expanding Genetic Medicine Services

8 months ago talkbio0Tagged Adeno-Associated Virus, Franklin Biolabs, gene therapy, Genetic Medicine Services, Jim Wilson

Jim Wilson, Franklin Biolabs, Gene Therapy, Genetic Medicine Services, Rare Diseases, Adeno-Associated Viruses (AAVs)

Navigating Complex Regulatory Landscapes: The Importance of External Support for Biotech Sponsors in IRB, IBC, DMCs, and EACs

9 months ago talkbio0Tagged 6-aminocaproic acid, Biotech sponsors, Clinical Trials, Clinical Trials Data Monitoring Committees, DMCs, Ethics Advisory Committees, Ethics Committees, Research, gene therapy, IBC, Institutional Biosafety Committee, Regulatory Compliance, research, Risk Management

Biotech sponsors, IRB (Institutional Review Board), IBC (Institutional Biosafety Committee), DMCs (Data Monitoring Committees), EACs (Ethics Advisory Committees), Regulatory compliance, Clinical trials, Gene therapy research, Risk management

BridgeBio Cuts Gene Therapy Budget by Over $50 Million Following Disappointing Early-Phase Data

9 months ago talkbio0Tagged BBP-631, BridgeBio, Budgets, Congenital adrenal hyperplasia, early-phase, gene therapy

BridgeBio, gene therapy, budget cut, early-phase data, CAH treatment, BBP-631, congenital adrenal hyperplasia

Voyager Therapeutics Secures $100M Upfront Payment in Expanded Gene Therapy Partnership with Novartis

9 months ago talkbio0Tagged Biotechnology, capsid discovery, gene therapy, Huntington Disease, Novartis, Spinal Muscular Atrophy, Tracer

Gene therapy, Novartis, Voyager Therapeutics, Huntington’s disease, Spinal muscular atrophy (SMA), TRACER capsid discovery platform, Biotechnology collaboration